NCPC(SH:600812) Sou Hu Cai Jing·2025-08-19 12:55Core Insights - The stock price of North China Pharmaceutical (600812) closed at 6.61 yuan on August 19, 2025, with a slight increase of 0.15% [1] - The company reported a total revenue of 5.275 billion yuan for the first half of 2025, reflecting a year-on-year growth of 0.84% [1] - The net profit attributable to shareholders reached 123 million yuan, showing a significant year-on-year increase of 71.56% [1] - The company has a debt ratio of 69.09%, indicating a relatively high level of leverage [1] Financial Performance - Total revenue for H1 2025: 5.275 billion yuan, up 0.84% year-on-year [1] - Net profit: 123 million yuan, up 71.56% year-on-year [1] - Non-recurring net profit: 120 million yuan, up 120.69% year-on-year [1] - Current ratio: 0.707, quick ratio: 0.516, debt ratio: 69.09% [1] Company Background - North China Pharmaceutical Co., Ltd. was established in 1992 and is located in Shijiazhuang, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.71573 billion yuan and a paid-in capital of 943.698816 million yuan [1] - The legal representative of the company is Wang Lixin [1] Investment and Intellectual Property - The company has made investments in 45 enterprises and participated in 5,000 bidding projects [2] - It holds 642 trademark registrations and 139 patents, along with 396 administrative licenses [2]